Amicus Therapeutics' Q2 revenue up more than expected on Galafold demand

Amicus Therapeutics

31/07/2025 12:17

Overview

Amicus Q2 2025 revenue of $154.7 mln beats analyst expectations

Galafold Q2 revenue rises 12% at CER, driven by patient demand

Co reiterates 2025 guidance for GAAP profitability in H2 2025

Outlook

Amicus expects 2025 revenue growth of 15% to 22%

Company anticipates GAAP profitability in H2 2025

Galafold revenue growth projected at 10% to 15% in 2025

Pombiliti + Opfolda revenue growth expected at 50% to 65% in 2025

Result Drivers

GALAFOLD DEMAND - Driven by patient demand and strong compliance, Galafold revenue rose 12% at CER

POMBILITI + OPFOLDA LAUNCHES - High demand and new launches in five countries fueled 58% revenue growth at CER

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$154.70 mln
$147.10 mln (11 Analysts)
Q2 EPS
-$0.08
Q2 Net Income
-$24.40 mln
Q2 Adjusted Operating Expenses
$30 mln
Q2 Operating Expenses
$30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Amicus Therapeutics Inc is $15.00, about 59.1% above its July 30 closing price of $6.13

The stock recently traded at 76 times the next 12-month earnings vs. a P/E of 79 three months ago

Press Release: ID:nGNX6DRVY

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)